Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Pfizer Inc (PFE) Price & Performance

YieldMax NVDA Option Income Strategy ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

YieldMax NVDA Option Income Strategy ETF vs Pfizer Inc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.66, while Pfizer Inc trades at $27.9 (market cap $158.39B). The key difference: Pfizer Inc pays a 6.19% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and Pfizer Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

NVDYPFE
Sector
Income / Options OverlayHealth
52-Week High
$17.21$29.02
52-Week Low
$11.58$23.60
Market Cap
$158.39B
Volume
29,869,932
Enterprise Value
$209.89B
Dividend Yield
6.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax NVDA Option Income Strategy ETF

NVDY trades at $12.82, down 1.23% today, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF generates consistent weekly dividends but faces structural limitations in capturing Nvidia's full upside potential. Recent analyst downgrades highlight concerns about declining volatility reducing option income effectiveness and potential NAV erosion despite the attractive 39.7% annualized distribution rate.

The outlook remains cautious as NVDY's strategy sacrifices long-term capital appreciation for income generation. While weekly distributions provide cash flow, the fund's structural cap on upside participation and reliance on Nvidia's volatility create headwinds. Investors seeking pure Nvidia exposure may find better alternatives, while income-focused investors should weigh the high distribution rate against potential principal erosion.

Pfizer Inc

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax NVDA Option Income Strategy ETF

NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.

Read more on NVDY

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE